Stockreport

Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting

PLUS THERAPEUTICS, Inc.  (PSTV) 
PDF Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in patients receiving [Read more]